Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Transmedics replaced its CFO in early December. Management also narrowed fourth-quarter guidance to the lower half of the previous range. Can Transmedics reaccelerate growth after this slowdown ...

On Dec. 2, Transmedics announced that its CFO, Stephen Gordon, would be retiring and that Gerardo Hernandez would take over the position. Investors typically do not like it when CFOs leave ...